How quality, supply resilience, manufacturing excellence and innovation are supporting the next generation of biologics.MILAN, Oct. 9, 2026 /PRNewswire/ — Europe's biologics sector is expanding as ageing populations and the rising burden of chronic, autoimmune and rare diseases increase demand for advanced therapies. The European biologics market was valued at an estimated US$123.75 billion in 2025 and is projected to grow at a CAGR of 8.1% from 2026 to 2035, reaching approximately US$269.65 billion by 2035, underscoring the need for faster development, dependable manufacturing and resilient regional supply. Continue Reading WuXi Biologics at CPHI Milan 2026: Empowering Biomanufacturing in Europe…